Elizabeth Halton

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

23h-index7.0kcitations66works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(61), Biomedical and Engineering Education(9), Biosimilars and Bioanalytical Methods(8), Acute Lymphoblastic Leukemia research(7), Advancements in Semiconductor Devices and Circuit Design(5)

Publications66 total

Data from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Supplementary Figures from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Supplementary Figures from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Supplementary Tables from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Figure S1, Figure S2, Figure S3, Figure S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Table S1, Table S2, Table S3, Table S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Tables from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Data from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Figure S1, Figure S2, Figure S3, Figure S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Table S1, Table S2, Table S3, Table S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
2023Open Access
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Nature Medicine·2022· 6 citedOpen Access
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Nature Medicine·2022· 286 citedOpen Access
A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
Blood·2021· 35 cited
Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Blood·2021· 1 cited
The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies
Blood·2021· 3 cited
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
Blood Advances·2021· 174 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Renier J. Brentjens(45), Isabelle Rivière(36), Michel Sadelain(34), Claudia Diamonte(31), Jae H. Park(30), Brigitte Sénéchal(21), Xiuyan Wang(20), Yvette Bernal(19), Bianca Santomasso(17), Craig S. Sauter(17), Elena Mead(16), Sergio Giralt(15), Terence J. Purdon(14), Miguel‐Angel Perales(13), Connie Lee Batlevi(13), Sean M. Devlin(12), Kevin J. Curran(11), Gunjan L. Shah(11), M. Lia Palomba(11), Mithat Gönen(10)